How NewLimit Plans to Extend Human Healthspan using Epigenetic Reprogramming

NewLimit, a biotechnology company focused on human longevity, led by Blake Byers, Brian Armstrong, Cathy O'Hare, and Jacob Kimmel, has secured an additional $45 million from Eli Lilly and Company, Duke Management Co., Section 32, and others, bringing its market capitalization to $1.62 billion. Insiders, including Kleiner Perkins, Dimension, Abstract, Human Capital, and Boost, also participated.

Significant progress has been made in developing medicines that rejuvenate aging cells through epigenetic reprogramming. Building on momentum since the Series B round, the advancements have set the stage for clinical studies expected to begin soon.

The belief that longevity medicines can enhance quality of life for all, beyond those affected by defined diseases, continues to drive efforts at NewLimit. The addition of new capital partners marks a strong endorsement of this mission and its global potential.

NewLimit is developing medicines that aim to reverse cellular aging through epigenetic reprogramming, restoring youthful function to old cells. The company’s approach targets the epigenetic controls that determine how genes are expressed, with the goal of rejuvenating cells without changing their identity.

Using AI-driven discovery platforms and advanced genomics, NewLimit identifies combinations of transcription factors that can make aged cells behave like young ones. Its initial programs focus on liver metabolism, immunology, and vascular health, tackling conditions such as alcohol-related liver disease, autoimmune disorders, and chronic kidney disease.

By translating breakthroughs in cellular reprogramming into RNA-based medicines, NewLimit aims to extend healthy human lifespan and address diseases of aging at their root cause.